ATOSB Knockout HeLa Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout population targeting the ATOSB gene in HeLa cells, offering a versatile loss-of-function model for functional genomics and cancer biology research. This polyclonal knockout cell population is generated through Cas9-mediated disruption of the ATOSB locus, eliminating the need for single-cell cloning and maintaining a heterogeneous genetic background that better preserves native cellular diversity. Researchers benefit from a cell pool that recapitulates varied editing outcomes while collectively abolishing ATOSB protein expression, facilitating robust downstream analyses without clonal artifacts. The product is supplied as a live cell stock, ready for expansion and immediate use in a broad spectrum of molecular and cellular assays.
The parental HeLa cell line, derived from cervical adenocarcinoma of Henrietta Lacks, is an HPV18-positive epithelial model extensively employed in cancer research. Its robust proliferative capacity, well-characterized signaling networks, and established protocols for transfection and drug treatment make it a premier system for dissecting oncogenic mechanisms and evaluating therapeutic interventions. This immortalized line??s historical significance and widespread adoption provide a reliable and reproducible foundation for interrogating gene function, particularly in the context of cervical carcinoma and virus-associated malignancies.
ATOSB encodes a putative transcriptional regulator implicated in the coordination of proliferation and differentiation programs. Mechanistically, ATOSB is positioned downstream of growth factor signaling and the MAPK cascade, integrating extracellular cues to modulate gene expression. It interacts with transcriptional coactivators CBP/p300 and the basal transcription machinery, assembling regulatory complexes at promoter regions. Through these interactions, ATOSB is believed to transcriptionally regulate downstream targets including cyclins, cyclin-dependent kinase inhibitors, and pro-apoptotic factors. Consequently, ATOSB knockout disrupts these transcriptional networks, leading to potential impairment of cell cycle progression and enhanced apoptotic vulnerability.
In the HeLa cervical carcinoma context, ATOSB disruption becomes particularly pertinent given the HPV18-driven dysregulation of transcriptional programs and cell cycle checkpoints. HPV oncoproteins E6 and E7 fundamentally alter host transcription and degrade tumor suppressors, creating a milieu where ATOSB??s regulatory functions may be co-opted or bypassed. Knocking out ATOSB in this background allows direct interrogation of its contribution to oncogenic phenotypes, such as unchecked proliferation and evasion of apoptosis. This model thus serves as a powerful tool to dissect how transcriptional modulators cooperate with viral oncoproteins in cervical cancer progression.
Key applications include investigating ATOSB??s role in transcriptional regulation and cervical cancer biology through RT-qPCR profiling of target genes, western blotting for cell cycle proteins, and flow cytometry-based cell cycle analysis. Proliferation and apoptosis assays further enable functional validation of ATOSB in growth control and drug response. The model is also suited for drug target validation studies where ATOSB-dependent pathways are interrogated with small-molecule inhibitors. For additional information, please contact Ascent Research.
